Amgen Inc. (NASDAQ:AMGN) Shares Bought by Thompson Investment Management Inc.

Thompson Investment Management Inc. lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 19,234 shares of the medical research company’s stock after acquiring an additional 381 shares during the period. Thompson Investment Management Inc.’s holdings in Amgen were worth $5,013,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP acquired a new position in shares of Amgen during the 3rd quarter worth $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen during the 3rd quarter worth $29,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen during the 4th quarter worth $36,000. Livelsberger Financial Advisory acquired a new position in shares of Amgen during the 3rd quarter worth $56,000. Finally, Kennebec Savings Bank acquired a new position in shares of Amgen during the 3rd quarter worth $57,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Down 1.4 %

NASDAQ AMGN opened at $293.54 on Friday. The stock has a market cap of $157.79 billion, a PE ratio of 38.88, a P/E/G ratio of 3.01 and a beta of 0.56. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The business has a 50 day moving average price of $272.26 and a two-hundred day moving average price of $303.21. The company has a quick ratio of 0.96, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. As a group, sell-side analysts predict that Amgen Inc. will post 20.59 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.24%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is presently 119.21%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on AMGN shares. Bank of America lifted their price target on Amgen from $256.00 to $275.00 and gave the stock an “underperform” rating in a research note on Thursday. Redburn Partners cut their target price on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Sanford C. Bernstein began coverage on shares of Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. TD Cowen boosted their target price on shares of Amgen from $381.00 to $383.00 and gave the company a “buy” rating in a research note on Monday, October 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price target on shares of Amgen in a report on Tuesday, October 22nd. Two analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $313.23.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.69% of the stock is currently owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.